The 33 references in paper A. Smirnov V., V. Dobronravov A., A. Zhloba A., R. Golubev V., А. Смирнов В., В. Добронравов А., А. Жлоба А., Р. Голубев В. (2006) “НОВЫЙ СПОСОБ КОРРЕКЦИИ ГИПЕРГОМОЦИСТЕИНЕМИИ У БОЛЬНЫХ, ПОЛУЧАЮЩИХ ЛЕЧЕНИЕ ХРОНИЧЕСКИМ ГЕМОДИАЛИЗОМ // A NEW METHOD OF CORRECTION OF HYPERHOMOCYSTEINEMIA IN CHRONIC HEMODIALYSIS PATIENTS” / spz:neicon:nefr:y:2006:i:3:p:31-37

1
Sirrs S, Duncan L, Djurdjev O et al. Homocyst(e)ine and vascular access complications in hemodialysis patients: insights into a complex metabolic relationships. Nephrol Dial Transplant 1999; 14: 738-743
(check this in PDF content)
2
Suliman ME, Qureshi AR, Barany P et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000; 57: 1727­ 1735
(check this in PDF content)
3
Mezzano D, Pais E, Aranda E et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 2001; 60: 1844-1851
(check this in PDF content)
4
Bayes B, Cruz Pastor M, Bonal J et al. Homocysteine, C- reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 106­ 112
(check this in PDF content)
5
Chauveau P, Chadefaux B, Coude M et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993; 43: S72-S77
(check this in PDF content)
6
Robinson K, Gupta A, Dennis V et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94: 2743-2748
(check this in PDF content)
7
Manns BJ, Burgess ED, Hyndman ME et al. Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am J Kidney Dis 1999; 34: 669-677
(check this in PDF content)
8
Kunz K, Petitjean P, Lisri M et al. Cardiovascular morbidity and endothelial dysfunction in chronic HD patients: is homocysteine the missing link? Nephrol Dial Transplant 1999; 14: 1934-1942
(check this in PDF content)
9
Zoccali C, Mallamaci F. Homocysteine and risk in end- stage renal disease: a matter of context. Kidney Int 2006; 69: 204-206
(check this in PDF content)
10
Dennis VW, Robinson K. Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int 1996; 50: S-11- S-17
(check this in PDF content)
11
Bostom AG, Lathrop L. Hyperhomocysteinemia in end- stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52: 10-20
(check this in PDF content)
12
Смирнов АВ, Добронравов ВА, Голубев РВ и др. Рас­ пространенность гипергомоцистеинемии в зависимости от стадии хронической болезни почек. Нефрология 2005; 9(2): 48-52
(check this in PDF content)
13
Bostom AG, Shemin D, Lapane KL et al. High dose B- vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996; 49: 147-152
(check this in PDF content)
14
Bostom AG, Shemin D, Gohn RY et al. Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients. Kidney Int 2001; 59: 246-252
(check this in PDF content)
15
Gonin JM, Nguyen H, Gonin R et al. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD. J Nephrol 2003; 16: 522-534
(check this in PDF content)
16
Hultberg B, Andersson A, Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 1993; 40: 230-234
(check this in PDF content)
17
Arnadottir M, Berg AL, Hegbrant J, Hultberg B. Influence of haemodialysis on plasma total homocysteine concentration. Nephrol Dial Transplant 1999; 14: 142-146
(check this in PDF content)
18
Vriese AS, Langlois M, Bernard D et al. Effect of dialyser membrane pore size on plasma homocysteine levels in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 2596-2600
(check this in PDF content)
19
Massy ZA. Potential strategies to normalize the levels of homocysteine in chronic renal failure patients. Kidney Int
(check this in PDF content)
20
3; 63 [Suppl. 84]: S134-S136 20. Suliman ME, Anderstam B, Lindholm B, Bergstrom J. Total, free, and protein-bound sulphur amino acids in uraemic patients. Nephrol Dial Transplant 1997; 12: 2332-2338
(check this in PDF content)
21
Жлоба АА, Иванова СЮ. Изучение свойств и выяв­ ление экспрессии рецептора активированного а2-макро- глобулина человека. Клиническая лабораторная диагностика 2002; 4: 7-11
(check this in PDF content)
22
Sass JO, Nakanishi T, Sato T et al. S-homocysteinylation of transthyretin is detected in plasma and serum of humans with different types of hyperhomocysteinemia. Biochem Biophys Res Commun 2003; 310: 242-246
(check this in PDF content)
23
Scholze A, Ringer C, Beige J. et al. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end stage renal failure. Circulation 2004; 109: 369-374
(check this in PDF content)
24
Friedman AN, Bostom AG, Laliberty P et al. The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis: a randomized, controlled study. Am J Kidney Dis 2003; 41: 442-446
(check this in PDF content)
25
Жлоба АА, Блашко ЭЛ. Определение общего гомо­ цистеина в плазме крови методом обращеннофазной жид­ костной хроматографии с использованием колонок С8 и С18 . Ученые записки СПбГМУ им.акад.И.П.Павлова 2004; XI (2): 20-25
(check this in PDF content)
26
Zhloba AA, Blashko EL. Liquid chromatographic determination of total homocysteine in blood plasma with photometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 800 (1-2): 275-280
(check this in PDF content)
27
Friedman AN, Bostom AG, Levey AS et al. Plasma total homocysteine levels among patients undergoing nocturnal versus standart hemodialysis. J Am Soc Nephrol 2002; 13: 265­ 268
(check this in PDF content)
28
Chambers JC, Ueland PM, Obeid OA et al. Improved vascular endothelial function after oral B vitamins: An effect mediated through reduced concentrations of free plasma homocysteine. Circulation 2000; 102(20):2479-2483
(check this in PDF content)
29
Refsum H, Smith AD, Ueland PM et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004; 50: 3-32
(check this in PDF content)
30
House AA, Wells GA, Donnelly JG et al. Randomised trial of high-flux vs low-flux haemodialysis: effects on homocysteine and lipids. Nephrol Dial Transplant 2000; 15: 1029-1034
(check this in PDF content)
31
Guttormsen AB, Ueland PM, Svarstad E, Refsum H. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 1997; 52: 495-502
(check this in PDF content)
32
Машковский МД. Лекарственные средства; в 2-х тт. Медицина, М., 1994; т.2; 221-222
(check this in PDF content)
33
Hurlbut KM, Maiorino RM, Mayersohn M et al. Determination and metabolism of dithiol chelating agents. XVI: Pharmacokinetics of 2,3-dimercapto-1-propanesulfonate after intravenous administration to human volunteers. J Pharmacol Exp Ther 1994; 268(2): 662-668
(check this in PDF content)